
Just signed the validation documents for our Monday launch of clinical quantitative Hepatitis B surface antigen (qHBsAg) testing at UW! (test code: HBSAGQ) qHBsAg is a fascinating analyte. It's the main eligibility criterion as well as primary outcome measure for HBV antiviral trials. The definition of functional cure in global guidelines. Approved in other countries for more than 15 years. But it was the poster child of a vicious cycle in diagnostic testing (no indication -> no FDA authorized test -> no testing -> no awareness). That all seems ready to change with the recent banger of clinical trial results for GSK's bepirovirsen reported in May (nejm.org/doi/full/10.1056/NE…). 20% of treated participants of functional cure for HBV compared to nobody in the placebo groups. Independently replicated in two cohorts. It's not quite sofosbuvir-level news, but what an opening for HBV cure. Anyway, back to the lab. Only half of people with HBV in the United States know they're infected and essentially no one knows their qHBsAg level and whether they could be eligible for this drug when it's approved. We've got to catch up quick (you can see GSK try here, usmahepa.gskusmedicalaffairs…). But there are no FDA-authorized qHBsAg tests available and won't be for many months. Enter the laboratory-developed test for qHBsAg. UW has performed qHBsAg testing for clinical trials for more than a decade, first for the NIH Hepatitis B Research Network and now for the Advancing Clinical Trials Globally Network. It's great to finally be able to make this test more widely available.














